ITI Capital Limited *(Formerly known as Inga Capital Limited)*
(A part of The Investment Trust of India Limited Group)
Regd office: Naman Midtown, A Wing, Unit No. 2102, 21st Floor
Senapati Bapat Marg, Elphinstone Road, Mumbai 400 013

ITI CAPITAL LIMITED

May 31, 2019

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Filing of Public Announcement and Board Resolution for Buyback of Equity Shares of Savita Oil Technologies Limited pursuant to the provisions of Regulation 7 and and 5(vii) of SEBI (Buy Back of Securities) Regulations, 2018, as amended ("Buyback Regulations")

With reference to the captioned matter, please find enclosed herewith the certified true copy of the Board Resolution passed by the Board of Directors of Savita Oil Technologies Limited at its meeting held on May 29, 2019 for the proposed Buyback of fully paid up Equity Shares not exceeding 2,51,000 (Two Lakh Fifty One Thousand) (representing up to 1.75% of the total number of Equity Shares of the Company) at a price of Rs. 1605/- (Rupees One Thousand Six Hundred and Five only) (including premium of Rs. 1595/-) per Equity Share payable in cash for an aggregate amount of up to Rs. 40,20,55,000 (Rupees Forty Crore Twenty Eight Lakh Fifty Five thousand only) excluding transaction costs such as brokerage, securities transaction tax, goods and service tax, stamp duty, etc., ("Transaction Cost") which represents 4.74% of the fully paid-up equity share capital and free reserves (including securities premium account) as per the standalone audited balance sheet of the Company as on March 31, 2019 (the last audited financial statements available as on the date of the Board meeting), on a proportionate basis through the tender offer ("Tender Offer") as prescribed under the Buyback Regulations from all the equity shareholders/beneficial owners of the Company who holds Equity Shares as on the record date i.e. June 12, 2019 ("Record Date").

With reference to the same the Public Announcement has been published in pursuance of the provisions of Regulation 7(i) of the Buyback Regulations. The said Public Announcement is published on May 31, 2019 in the following newspapers.

- Financial Express (English Edition)
- Jansatta (Hindi Edition)
- Mumbai Lakshadeep (Marathi –Edition)

Please find enclosed herewith newspaper clipping and soft copy in pdf format of Public Announcement published in Financial Express on May 31, 2019.

Kindly receive the same in order and take the same on records.

Thanking you,

Yours faithfully,

For ITI Capital Limited
(Formerly Inga Capital Limited)

M. B. Pandhi

ITI CAPITAL LTD. MUMBAI

Name: Mihir Pandhi
Designation: AVP- Investment Banking
Contact No.: +91 22 4031 3489
Email: savita.buyback2019@iticapital.in

Encl: As above

Glenmark PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.
Tel: 91 22 4018 9999 **Fax:** 91 22 4018 9986 **Email:** complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of Audited Financial Results for the Quarter and Year Ended 31 March, 2019

(₹ in Millions)

	Particulars (Refer notes below)	Standalone (Ind AS)					Consolidated (Ind AS)					Consolidated (IFRS)				
		Quarter ended 31-03-2019 (Audited)	Quarter ended 31-12-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited)	Year ended 31-03-2019 (Audited)	Year ended 31-03-2018 (Audited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 31/12/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited)	Year ended 31/03/2019 (Audited)	Year ended 31/03/2019 (Audited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 31/12/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited)	Year ended 31/03/2019 (Audited)	Year ended 31/03/2018 (Audited)
I	Revenue from operations															
	(a) Net sales	15,307.63	15,998.97	13,072.07	61,311.40	52,434.15	25,260.82	25,097.79	22,478.93	97,050.84	89,722.32	25,260.82	25,097.79	22,478.93	97,050.84	89,722.32
	(b) Other operating income	565.16	321.39	1,389.47	1,737.27	3,007.93	373.92	452.66	319.23	1,603.84	1,308.38	373.92	452.66	319.23	1,603.84	1,308.38
	Total revenue from operations	15,872.79	16,320.36	14,461.54	63,048.67	55,442.08	25,634.74	25,550.45	22,798.16	98,654.68	91,030.70	25,634.74	25,550.45	22,798.16	98,654.68	91,030.70
II	Other income	1,683.89	(846.41)	439.61	4,756.14	1,799.92	390.57	(1,090.15)	695.52	2,081.37	914.00	390.58	(1,090.24)	695.52	2,081.12	914.00
III	Total income (I + II)	17,556.68	15,473.95	14,901.15	67,804.81	57,242.00	26,025.31	24,460.30	23,493.68	1,00,736.05	91,944.70	26,025.32	24,460.21	23,493.68	1,00,735.80	91,944.70
IV	Expenses															
	(a) Cost of materials consumed	2,548.89	5,365.47	4,568.55	15,858.51	16,480.25	6,144.64	7,318.05	6,149.42	24,447.12	21,501.10	6,144.64	7,318.05	6,149.42	24,447.12	21,501.10
	(b) Purchase of stock-in-trade	476.85	908.24	632.69	3,012.95	2,881.77	1,718.19	2,914.14	1,734.00	9,762.98	7,547.45	1,718.19	2,914.14	1,734.00	9,762.98	7,547.45
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,168.80	(24.78)	275.75	4,718.11	1,397.14	744.39	(1,612.05)	(40.39)	(586.68)	1,337.12	744.39	(1,612.05)	(40.39)	(586.68)	1,337.12
	(d) Employee benefits expense	2,242.26	2,320.86	2,046.92	9,699.80	8,956.71	4,945.85	5,030.81	4,642.73	20,560.70	18,718.41	4,945.85	5,030.81	4,642.73	20,560.70	18,718.41
	(e) Finance costs	526.08	551.82	507.22	2,238.14	1,908.98	819.11	885.35	743.88	3,345.85	2,855.67	819.11	885.35	743.88	3,345.85	2,855.67
	(f) Depreciation and amortisation expense	263.48	257.04	238.72	1,062.79	959.27	809.70	831.01	735.32	3,259.05	3,018.76	871.24	935.58	894.24	3,685.27	3,540.67
	(g) Other expenses	4,748.51	4,257.02	4,131.46	16,484.52	14,716.17	8,440.36	7,552.70	7,044.05	28,612.56	25,772.89	8,440.36	7,552.70	7,046.35	28,612.56	25,776.33
	Total expenses (IV)	13,974.87	13,635.67	12,401.31	53,074.82	47,300.29	23,622.24	22,920.01	21,009.01	89,401.58	80,751.40	23,683.78	23,024.58	21,170.23	89,827.80	81,276.75
V	Profit/(loss) before exceptional items and tax (III - IV)	3,581.81	1,838.28	2,499.83	14,729.99	9,941.71	2,403.07	1,540.29	2,484.67	11,334.47	11,193.30	2,341.54	1,435.63	2,323.45	10,908.00	10,667.95
VI	Exceptional items (Refer note 7)	-	-	-	(3,451.85)	-	-	-	-	(1,671.82)	-	-	-	-	(1,671.82)	-
VII	Profit/(loss) before tax (V - VI)	3,581.81	1,838.28	2,499.83	18,181.84	9,941.71	2,403.07	1,540.29	2,484.67	13,006.29	11,193.30	2,341.54	1,435.63	2,323.45	12,579.82	10,667.95
VIII	Tax expense :															
	Current tax	848.44	309.32	598.40	3,834.95	2,018.21	874.25	629.89	961.43	4,765.42	3,256.90	874.25	629.89	948.64	4,765.42	3,244.11
	Deferred tax	(79.51)	(165.26)	(22.30)	(536.14)	(735.11)	(87.80)	(253.01)	6.97	(1,009.06)	(102.30)	(95.68)	(270.93)	(135.56)	(1,102.30)	(318.99)
IX	Profit/(loss) for the period from continuing operations (VII-VIII)	2,812.88	1,694.22	1,923.73	14,883.03	8,658.61	1,616.62	1,163.41	1,516.27	9,249.93	8,038.70	1,562.97	1,076.67	1,510.37	8,916.70	7,742.83
X	Profit/(loss) before tax from discontinuing operations	-	398.25	440.86	2,028.34	2,246.54	-	-	-	-	-	-	-	-	-	-
XI	Tax expense of discontinuing operations :															
	Current tax	-	119.25	135.12	650.29	688.56	-	-	-	-	-	-	-	-	-	-
	Deferred tax	-	14.51	14.35	39.96	73.12	-	-	-	-	-	-	-	-	-	-
XII	Profit/(loss) for the period from discontinuing operations (X-XI)	-	264.49	291.39	1,338.09	1,484.86	-	-	-	-	-	-	-	-	-	-
XIII	Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	2,812.88	1,958.71	2,215.12	16,221.12	10,143.47	1,616.62	1,163.41	1,516.27	9,249.93	8,038.70	1,562.97	1,076.67	1,510.37	8,916.70	7,742.83
XIV	Other comprehensive income															

XIII	Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	2,812.88	1,958.71	2,215.12	16,221.12	10,143.47	1,616.62	1,163.41	1,516.27	9,249.93	8,038.70	1,562.97	1,076.67	1,510.37	8,916.70	7,742.8
XIV	Other comprehensive income															
	A (i) Items that will not be reclassified to profit or loss	(13.42)	(17.61)	36.41	(54.38)	(10.20)	(274.54)	(16.69)	9.93	(259.39)	41.96	(274.54)	(16.69)	9.93	(259.39)	41.9
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.69	6.15	(12.60)	19.00	3.53	38.78	6.03	(9.15)	45.80	(3.25)	38.78	6.03	(9.15)	45.80	(3.25)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	(951.38)	566.06	(511.28)	(3,710.57)	(778.78)	(948.75)	527.52	(463.92)	(3,732.65)	(696.17)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(300.25)	(56.92)	-	(229.50)	-	(300.25)	(56.92)	-	(229.50)	
XV	Total comprehensive income	2,804.15	1,947.25	2,238.93	16,185.74	10,136.80	129.23	1,661.89	1,005.77	5,096.27	7,298.63	78.21	1,536.61	1,047.23	4,740.96	7,085.3
XVI	Total comprehensive income attributable to:						0.10	0.09	0.47	0.11	0.92	0.10	0.09	0.47	0.11	0.9
	- Non-controlling interests	-	-	-	-	-	129.13	1,661.80	1,005.30	5,096.16	7,297.71	78.11	1,536.52	1,046.76	4,740.85	7,084.4
	- Owners of the Company	2,804.15	1,947.25	2,238.93	16,185.74	10,136.80	-	-	-	55,769.67	51,352.60	-	-	-	59,670.14	55,608.37
XVII	Other equity	-	-	-	1,19,138.72	1,03,632.24										
XVIII	Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised for quarters)															
	Basic EPS (in Rupees)	9.97	6.00	6.82	52.75	30.69	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
	Diluted EPS (in Rupees)	9.97	6.00	6.82	52.74	30.69	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
XIX	Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised for quarters)															
	Basic EPS (in Rupees)	-	0.94	1.03	4.74	5.26	-	-	-	-	-	-	-	-	-	
	Diluted EPS (in Rupees)	-	0.94	1.03	4.74	5.26	-	-	-	-	-	-	-	-	-	
XX	Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised for quarters)															
	Basic EPS (in Rupees)	9.97	6.94	7.85	57.49	35.95	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44
	Diluted EPS (in Rupees)	9.97	6.94	7.85	57.49	35.95	5.73	4.12	5.37	32.78	28.49	5.54	3.82	5.35	31.60	27.44

Notes:

1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
2. The above results were reviewed by the Audit Committee at its meeting held on 28 May, 2019 and approved at the meeting of the Board of Directors held on 29 May, 2019.
3. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have performed an audit of the standalone and consolidated financial results of the Company for the financial year ended 31 March, 2019. There are no modifications in the audit report.
4. The figures for the quarter ended 31 March are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.
5. On 1 January 2019, the Company completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company.
6. During the year, the Company bought back U.S.$86,500,000 in aggregate principal amount of the Foreign Currency Convertible Bonds (FCCB). As of 31 March, 2019, U.S.$113,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability of Rs. 153.72 million.
7. Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the year ended 31 March, 2019, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the year ended 31 March 2019 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million.
8. Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for quarter and year ended 31 March, 2019 are not comparable with previous periods presented.
9. The disclosure of statement of assets and liabilities as per Regulation 33(3)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are an integral part of these results.
10. The Board has recommended a final dividend of 200% .i.e. Rs. 2 per equity share of face value of Re. 1 each for financial year 2018-19. The payment is subject to the approval of the shareholders in the ensuing annual general meeting.
11. Effective 1 April, 2018, the Company adopted Ind AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of Ind AS 115 or IFRS 15, as the case may be.
12. The list of subsidiaries as of 31 March, 2019 is provided in Annexure A.
13. The Company operates in one reportable business segment i.e., Pharmaceuticals.
14. As at 31 March, 2019, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
15. Diluted EPS has been computed considering the effect of conversion of ESOPs.
16. Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited
Annexure A

Glenmark Pharmaceuticals Limited
Statement of assets and liabilities
(All amounts in million of Indian Rupees, unless otherwise stated)

	STANDALONE		CONSOLIDATED			
	Ind AS As at 31.03.2019 Audited	Ind AS As at 31.03.2018 Audited	Ind AS As at 31.03.2019 Audited	Ind AS As at 31.03.2018 Audited	IFRS As at 31.03.2019 Audited	IFRS As at 31.03.2018 Audited
ASSETS						
Non current assets						
Property, plant and equipment	13,081.67	15,766.49	20,978.12	18,958.10	23,688.89	21,733.74
Capital work-in-progress	2,091.79	3,540.42	12,343.68	9,933.40	12,708.34	10,347.15
Goodwill	-	-	547.35	521.04	547.35	521.04
Other intangible assets	1,053.16	1,224.73	15,177.07	10,816.38	17,289.96	13,296.47
Intangible assets under development	770.16	656.33	1,645.70	1,285.32	1,645.70	1,285.32
Financial assets						
(i) Investments	32,687.52	32,126.84	296.59	146.61	296.59	146.61
(ii) Loans and advances	62,639.26	33,028.48	-	-	-	-
(iii) Other financial assets	368.01	380.91	501.87	401.18	501.87	401.18
Deferred tax assets (net)	7,121.33	6,606.15	13,829.51	13,202.60	12,905.43	12,201.76
Other non-current assets	202.54	565.85	599.77	802.23	236.00	389.36
Total non- current assets	1,20,015.44	93,896.20	65,919.66	56,066.86	69,820.13	60,322.63
Current assets						
Inventories	9,112.09	11,111.80	22,520.74	20,305.85	22,520.74	20,305.85
Financial assets						
(i) Investments	-	-	-	-	-	-
(ii) Trade receivables	20,871.31	38,289.08	21,945.90	23,318.07	21,945.90	23,318.07
(iii) Cash and cash equivalents	2,549.97	1,760.47	9,362.78	12,333.56	9,362.78	12,333.56
(iv) Bank balance other than cash and cash equivalents	14.87	13.35	14.87	13.35	14.87	13.35
(v) Other financial assets	13,123.42	1,937.10	2,802.66	3,856.42	2,802.66	3,856.42
Current tax assets	-	-	-	-	-	-
Other current assets	5,739.87	5,640.71	10,321.30	10,059.67	10,321.30	10,059.67
Total current assets	51,411.53	58,752.51	66,968.25	69,886.92	66,968.25	69,886.92
Total assets	1,71,426.97	1,52,648.71	1,32,887.91	1,25,953.78	1,36,788.38	1,30,209.55
EQUITY AND LIABILITIES						
Equity						
Equity share capital	282.17	282.17	282.17	282.17	282.17	282.17
Other equity	1,19,138.72	1,03,632.24	55,769.67	51,352.60	59,670.14	55,608.37
Minority interest	-	-	(3.77)	(3.70)	(3.77)	(3.70)
Liabilities						
Non-current liabilities						
Financial liabilities						
(i) Borrowings	28,314.52	26,860.29	35,737.54	41,417.78	35,737.54	
(ii) Other financial liabilities						

2 The above results were reviewed by the Audit Committee at its meeting held on 28 May, 2019 and approved at the meeting of the Board of Directors held on 29 May, 2019.

3 In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have performed an audit of the standalone and consolidated financial results of the Company for the financial year ended 31 March, 2019. There are no modifications in the audit report.

4 The figures for the quarter ended 31 March are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.

5 On 1 January 2019, the Company completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company.

6 During the year, the Company bought back U.S.$86,500,000 in aggregate principal amount of the Foreign Currency Convertible Bonds (FCCB). As of 31 March, 2019 , U.S.$113,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability of Rs. 153.72 million.

7 Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the year ended 31 March, 2019, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the year ended 31 March 2019 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million.

8 Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for quarter and year ended 31 March, 2019 are not comparable with previous periods presented.

9 The disclosure of statement of assets and liabilities as per Regulation 33(3)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are an integral part of these results.

10 The Board has recommended a final dividend of 200% .i.e. Rs. 2 per equity share of face value of Re. 1 each for financial year 2018-19. The payment is subject to the approval of the shareholders in the ensuing annual general meeting.

11 Effective 1 April, 2018, the Company adopted Ind AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of Ind AS 115 or IFRS 15, as the case may be.

12 The list of subsidiaries as of 31 March, 2019 is provided in Annexure A.

13 The Company operates in one reportable business segment i.e., Pharmaceuticals.

14 As at 31 March, 2019, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

15 Diluted EPS has been computed considering the effect of conversion of ESOPs.

16 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Non current assets						
Property, plant and equipment	13,081.67	15,766.49	20,978.12	18,556.19	12,708.34	10,347.15
Capital work-in-progress	2,091.79	3,540.42	12,343.68	9,933.40	547.35	521.04
Goodwill	-	-	547.35	521.04	17,289.96	13,296.47
Other intangible assets	1,053.16	1,224.73	15,177.07	10,816.38	1,645.70	1,285.32
Intangible assets under development	770.16	656.33	1,645.70	1,285.32	-	-
Financial assets						
(i) Investments	32,687.52	32,126.84	296.59	146.61	296.59	146.61
(ii) Loans and advances	62,639.26	33,028.48	-	-	-	-
(iii) Other financial assets	368.01	380.91	501.87	401.18	501.87	401.18
Deferred tax assets (net)	7,121.33	6,606.15	13,829.51	13,202.60	12,905.43	12,201.76
Other non-current assets	202.54	565.85	599.77	802.23	236.00	389.36
Total non- current assets	1,20,015.44	93,896.20	65,919.66	56,066.86	69,820.13	60,322.63
Current assets						
Inventories	9,112.09	11,111.80	22,520.74	20,305.85	22,520.74	20,305.85
Financial assets	-	-	-	-	-	-
(i) Investments	20,871.31	38,289.08	21,945.90	23,318.07	21,945.90	23,318.07
(ii) Trade receivables	2,549.97	1,760.47	9,362.78	12,333.56	9,362.78	12,333.56
(iii) Cash and cash equivalents	14.87	13.35	14.87	13.35	14.87	13.35
(iv) Bank balance other than cash and cash equivalents	13,123.42	1,937.10	2,802.66	3,856.42	2,802.66	3,856.42
(v) Other financial assets	-	-	-	-	-	-
Current tax assets	5,739.87	5,640.71	10,321.30	10,059.67	10,321.30	10,059.67
Other current assets	51,411.53	58,752.51	66,968.25	69,886.92	66,968.25	69,886.92
Total current assets	1,71,426.97	1,52,648.71	1,32,887.91	1,25,953.78	1,36,788.38	1,30,209.55
Total assets						
EQUITY AND LIABILITIES						
Equity						
Equity share capital	282.17	282.17	282.17	282.17	282.17	282.17
Other equity	1,19,138.72	1,03,632.24	55,769.67	51,352.60	59,670.14	55,608.37
Minority interest	-	-	(3.77)	(3.70)	(3.77)	(3.70)
Liabilities						
Non-current liabilities						
Financial liabilities						
(i) Borrowings	28,314.52	26,860.29	35,737.54	41,417.78	35,737.54	41,417.78
(ii) Other financial liabilities	885.06	26.00	885.06	26.00	885.06	26.00
Deferred tax liabilities (net)	-	-	-	-	-	-
Other non- current liabilities	-	-	6.30	-	6.30	-
Total non-current liabilities	29,199.58	26,886.29	36,628.90	41,443.78	36,628.90	41,443.78
Current liabilities						
Financial liabilities						
(i) Borrowings	3,030.30	2,950.44	3,030.24	2,950.44	3,030.24	2,950.44
(ii) Other financial liabilities	1,412.12	1,848.86	9,012.69	5,657.89	9,012.69	5,657.89
(iii) Trade payables						
- Total outstanding dues of other than Micro enterprises and Small enterprises	15,787.57	14,571.28	21,097.52	17,719.59	21,097.52	17,719.59
- Total outstanding dues of Micro enterprises and Small enterprises	889.07	978.25	1,109.99	978.25	1,109.99	978.25
Other current liabilities	469.90	567.19	1,119.44	1,248.12	1,119.44	1,248.12
Provisions	853.30	783.58	4,383.50	4,040.38	4,383.50	4,040.38
Current tax liabilities (Net)	364.24	148.41	457.56	284.26	457.56	284.26
Total current liabilities	22,806.50	21,848.01	40,210.94	32,878.93	40,210.94	32,878.93
Total liabilities	52,006.08	48,734.30	76,839.84	74,322.71	76,839.84	74,322.71
Total equity and liabilities	1,71,426.97	1,52,648.71	1,32,887.91	1,25,953.78	1,36,788.38	1,30,209.55

Glenmark Pharmaceuticals Limited

Annexure A

List of entities included in the consolidated financial results for the year ended 31 March 2019

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. **2.**Glenmark Pharmaceuticals Europe Ltd., U.K. **3.**Glenmark Pharmaceuticals S.R.O. **4.**Glenmark Pharmaceuticals SK, S.R.O. **5.**Glenmark Pharmaceuticals S. A. **6.**Glenmark Holding S.A. **7.**Glenmark Pharmaceuticals S.R.L **8.**Glenmark Pharmaceuticals SP z.o.o. **9.**Glenmark Pharmaceuticals Inc. (formerly Glenmark Generics Inc.) **10.**Glenmark Therapeutics Inc. **11.**Glenmark Farmaceutica Ltda **12.**Glenmark Generics S.A **13.**Glenmark Pharmaceuticals Mexico, S.A. DE C.V. **14.**Glenmark Pharmaceuticals Peru SAC **15.**Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) **16.**Glenmark Uruguay S.A. **17.**Glenmark Pharmaceuticals Venezuela, C.A **18.**Glenmark Dominicana SRL **19.**Glenmark Pharmaceuticals Egypt S.A.E. **20.**Glenmark Pharmaceuticals FZE **21.**Glenmark Impex L.L.C **22.**Glenmark Philippines Inc. **23.**Glenmark Pharmaceuticals (Nigeria) Ltd. **24.**Glenmark Pharmaceuticals Malaysia Sdn Bhd **25.**Glenmark Pharmaceuticals (Australia) Pty Ltd **26.**Glenmark South Africa (pty) Ltd **27.**Glenmark Pharmaceuticals South Africa (pty) Ltd **28.**Glenmark Pharmaceuticals (Thailand) Co. Ltd **29.**Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) **30.**Glenmark Arzneimittel Gmbh **31.**Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) **32.**Glenmark Pharmaceuticals Kenya Ltd **33.**Glenmark Therapeutics AG **34.**Viso Farmaceutica S.L., Spain **35.**Glenmark Specialty SA **36.**Glenmark Pharmaceuticals Distribution s.r.o. **37.**Glenmark Pharmaceuticals Nordic AB **38.**Glenmark Ukraine LLC **39.**Glenmark-Pharmaceuticals Ecuador S.A. **40.**Glenmark Pharmaceuticals Singapore Pte. Ltd. **41.**Glenmark Biotherapeutics SA **42.**Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

Mumbai, 29 May, 2019

For and on behalf of the Board of Directors

Glenn Saldanha
Chairman & Managing Director

CLASSIFIED CENTRES IN MUMBAI

Pallavi Advtg. Dadar (W), Mobile: 9869109765

Shree Swami Samarth Advertising, Dadar (W), Phone : 24440631 Mobile : 9869131962

Stylus Arts, Dadar (W), Phone : 24304897

Time Advertising, Matunga (W), Phone : 2448 6191

Vijaya Agencies, Dadar (W), Phone : 2422 5672, Mobile : 9930640689

Media Junction, Matunga (W), Phone: 022-66393184/ 022-66332340 Mobile: 9820295353/ 9821656198

Space Age Advertising, Bandra (E), Phone : 26553207 Mobile : 9869666222

Kirti Agencies, Khar (W), Phone : 26047543.

Krishna Advertising, Santacruz (E), Phone : 26651754 Mobile : 9324868171.

AD Support Advertising, Santacruz (W), Mobile: 9869463650

Gauri Press Communication, Vile Parle (E), Phone : 2617 6310 Mobile: 9820069565

Carl Advertising, Andheri (W), Phone : 6696 3441 / 42.

Lokhandwala Advertising, Andheri (W), Phone : 26364274 / 26316960.

Prime Publicity Services, Andheri (E), Phone : 26839686 / 26830304.

Zoyz Creations Andheri (W), Phone: 022-26288794 Mobile: 9833364551/ 9820199918

B V Advertisers, Jogeshwari (W) Phone: 26768888 Mobile: 9820123000

Neha Agency, Goregaon (E), Phone : 2927 5033. Mobile : 9819099563.

Shark Enterprises, Goregaon (E), Phone: 022-26863587

Adresult Services, Goregaon (W) Phone : 28762157 / 28726291.

Samartha Advertiser Pvt. Ltd., Goregaon (E), Phone: 26852294 Mobile: 9594969627

Target Media, Goregaon (E), Mobile: 8692959648/ 9702307711

Bijal Visual Ads., Malad (W), Phone: 28835457/ 28805487 Mobile: 9322365715

Noble Publicity Service, Malad (W), Phone : 28881426 / 28881518.

Synergy Advertising, Malad (W), Phone : 28891428 / 22811012

Arihant Advertising, Kandivali (W) Phone : 28626679 Mobile: 9004992568

New Boom Ads, Kandivali (W), Phone : 28640221.

Pranav Publicity, Kandivali (W) Phone : 42759999. Mobile : 9820295421.

Vikson Advertising Agency Kandivali (W), Phone : 28645005 Mobile : 9820433200

Express Advertising, Borivali (W), Phone : 2833 7799 /2833 9977. Mobile: 9820401077

Falcon Multimedia Pvt. Ltd., Borivali (E) Mobile : 9833226463

Nikkarge Advertising, Borivali (W), Phone : 28921255 Mobile : 9322210176

Ashansi Advertising & Press Relations, Mira Road (E) Phone: 022-28114235 Mobile: 9833933502

M.S. Advertising, Bhayander (E), Phone: 022-28160100 Mobile: 9769711737

Sugo Advertising, Vasai (W), Phone : 7756982329/ 7028565571

Mayuresh Publicity, Virar (W), Phone : 0250 – 2503913. Mobile : 9923935556

Plasma Advertising, Panvel. Phone : 022-27461970

Ronak Advertising, Vashi. Phone : 71012345 Mobile: 9324102060/ 9820152753

Rahul Advertising Vashi, Phone: 022-65119998 Mobile: 9820200044

Making A Small Message Go A Long Way .....

Classifieds